AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21233256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy management and/or disease management including motivational interviewing (MI) counseling every 6 months over 2 years
Number of subjects: 750
Study 18274885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (SP)
Number of subjects: 352
Study 18274885 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 352
Study 16927525 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador Quercus special (IQ; rich in mistletoe lectin)
Number of subjects: 47
Study 16927525 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador Pinus (IP; poor in mistletoe lectin but rich in viscotoxin)
Number of subjects: 47
Study 16927525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 47
Study 12675544 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized 3-hour training session on using the World Wide Web to research patient-related questions
Number of subjects: 80
Study 10922131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (salmeterol 50 microg twice daily + fluticasone propionate 100 microg twice daily)
Number of subjects: 257
Study 10922131 — intervention group
Group type: COMPARATOR
Intervention: Concurrent therapy (salmeterol 50 microg twice daily + fluticasone propionate 100 microg twice daily via separate inhalers)
Number of subjects: 257
Study 10922131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 257
Study 10922131 — intervention group
Group type: COMPARATOR
Intervention: Concurrent therapy
Number of subjects: 257
Study 10922131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 257
Study 8880836 — intervention group
Group type: COMPARATOR
Intervention: Crohn's disease patients
Number of subjects: 30
Study 8880836 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 30
Study 8880836 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 30
Study 8880836 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease and IBS patients
Number of subjects: 30
Study 1563299 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 24
Study 1563299 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration anaesthesia
Number of subjects: 24
Study 1563299 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration anaesthesia plus local wound hypothermia with ice bags
Number of subjects: 24
Study 3906941 — intervention group
Group type: EXPERIMENTAL
Intervention: Human antilipopolysaccharide (anti-LPS)-specific globulin (LG-1)
Number of subjects: 34
Study 3906941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 34
Study 3906941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 31779994 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection (100 ml/day) for 9.28±3.75 days followed by Shenmai capsule (3.6 g/day) for 30 days in addition to cardiac rehabilitation
Number of subjects: 166
Study 31779994 — intervention group
Group type: COMPARATOR
Intervention: Control group (only cardiac rehabilitation)
Number of subjects: 166
Study 29717512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-sirolimus eluting stents (SES)
Number of subjects: 330
Study 29717512 — intervention group
Group type: COMPARATOR
Intervention: Everolimus eluting stents (EES)
Number of subjects: 330
Study 27806972 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 1315 mg catechins (843 mg EGCG), 4 capsules daily for 12 months
Number of subjects: 936
Study 27806972 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 4 capsules daily for 12 months
Number of subjects: 936
Study 25024178 — intervention group
Group type: EXPERIMENTAL
Intervention: Choosing between similarly high-valued products
Number of subjects: 0
Study 25024178 — intervention group
Group type: COMPARATOR
Intervention: No high-value option
Number of subjects: 0
Study 25024178 — intervention group
Group type: COMPARATOR
Intervention: Only one option was highly valued
Number of subjects: 0
Study 25024178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal mPFC activity
Number of subjects: 0
Study 25024178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral regions activity
Number of subjects: 0
Study 25024178 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity levels across individual items
Number of subjects: 0
Study 23648200 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet adhesives (APA)
Number of subjects: 0
Study 23648200 — intervention group
Group type: COMPARATOR
Intervention: Control (low risk group undergoing radiation only)
Number of subjects: 0
Study 20523295 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital drainage system with fast-track chest tube removal protocol
Number of subjects: 0
Study 20523295 — intervention group
Group type: COMPARATOR
Intervention: Traditional drainage system with subjective visual air leak assessment
Number of subjects: 0
Study 18473339 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive behavior therapy (REBT)
Number of subjects: 170
Study 18473339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 170
Study 18473339 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (fluoxetine)
Number of subjects: 170
Study 16026803 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta-1a, 22 or 44 mcg subcutaneously three times weekly during years 3 and 4
Number of subjects: 0
Study 12148100 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral dialysis (energy flow rate: DeltaE = -0.22 +/- 0.29 kJ/kg x h)
Number of subjects: 116
Study 12148100 — intervention group
Group type: COMPARATOR
Intervention: Isothermic dialysis (energy flow rate: DeltaE = -0.90 +/- 0.35 kJ/kg x h)
Number of subjects: 116
Study 9710006 — intervention group
Group type: COMPARATOR
Intervention: HLA-DRB1*0803 in C. jejuni + GM1 + GBS group
Number of subjects: 81
Study 9710006 — intervention group
Group type: COMPARATOR
Intervention: TCR, HLA class I and II genetic markers
Number of subjects: 81
Study 7609864 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins (thiamine diphosphate 100 mg, pyridoxsine-HCl 200 mg, cyanocobalamin 20 micrograms, p.o.)
Number of subjects: 38
Study 7609864 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (diclofenac-Na, 50 mg, p.o.)
Number of subjects: 38
Study 7609864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2147029 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine, 14.5 mg once daily
Number of subjects: 163
Study 2147029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 381093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times daily)
Number of subjects: 15
Study 381093 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Mylanta II, 30 ml four times daily and PRN)
Number of subjects: 15
Study 381093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 15
Study 381093 — intervention group
Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 15
Study 30285054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amitriptyline (25 mg/d)
Number of subjects: 146
Study 30285054 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (benztropine mesylate, 1 mg/d)
Number of subjects: 146
Study 26868507 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 39
Study 26868507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 39
Study 26868507 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Number of subjects: 39
Study 25068637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 4 weeks for 20 weeks, then as needed (PRN) thereafter.
Number of subjects: 177
Study 25068637 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment every 4 weeks for 20 weeks, then sham thereafter.
Number of subjects: 177
Study 22343361 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-5 days of antibiotic treatment (group 1)
Number of subjects: 66
Study 22343361 — intervention group
Group type: COMPARATOR
Intervention: 7-10 days of antibiotic treatment (group 2)
Number of subjects: 66
Study 20357312 — intervention group
Group type: EXPERIMENTAL
Intervention: Early group intervention based on cognitive‐behavioural principles
Number of subjects: 217
Study 20357312 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 217
Study 17425757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lombotomy mini-incision technique
Number of subjects: 60
Study 17425757 — intervention group
Group type: COMPARATOR
Intervention: Subcostal mini-incision technique
Number of subjects: 60
Study 17425757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60
Study 15728647 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 3137
Study 15728647 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment
Number of subjects: 3137
Study 12195449 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient rehabilitative treatment for 6 weeks, 6 days a week.
Number of subjects: 111
Study 12195449 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group with self-exercises at home.
Number of subjects: 111
Study 9783376 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg GTN
Number of subjects: 97
Study 9783376 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg GTN
Number of subjects: 97
Study 9783376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 97
Study 7826118 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration
Number of subjects: 77
Study 7826118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspiration)
Number of subjects: 77
Study 3046407 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen extract alone (n = 24)
Number of subjects: 51
Study 3046407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of alder, birch and hazel pollen extracts (n = 27)
Number of subjects: 51
Study 30005989 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial cellulose sheets
Number of subjects: 40
Study 30005989 — intervention group
Group type: COMPARATOR
Intervention: Silver sulphadiazine cream 10mg/g
Number of subjects: 40
Study 27001317 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient balm applied twice a day for 28 days
Number of subjects: 54
Study 27001317 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient balm
Number of subjects: 54
Study 27001317 — intervention group
Group type: COMPARATOR
Intervention: Control group (hygiene product only)
Number of subjects: 54
Study 26313719 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous hydrocortisone administered during anesthetic induction
Number of subjects: 22
Study 26313719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hydrocortisone administered)
Number of subjects: 22
Study 23210695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (Cryo) ablation
Number of subjects: 80
Study 23210695 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 80
Study 23210695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (Cryo) ablation without RF
Number of subjects: 80
Study 23210695 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation only
Number of subjects: 80
Study 21835638 — intervention group
Group type: EXPERIMENTAL
Intervention: GA + TEA
Number of subjects: 30
Study 21835638 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 30
Study 18178205 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial examination of ACF detection
Number of subjects: 78
Study 18178205 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examination after 1 year
Number of subjects: 78
Study 17131714 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (0 ppm F; PD)
Number of subjects: 13
Study 17131714 — intervention group
Group type: COMPARATOR
Intervention: Dose response control dentifrice (250 ppm F; DD)
Number of subjects: 13
Study 17131714 — intervention group
Group type: COMPARATOR
Intervention: Clinically tested fluoride dentifrice (1100 ppm F; FD)
Number of subjects: 13
Study 17131714 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice (1150 ppm F + 5% KNO3; TD)
Number of subjects: 13
Study 12486753 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for defining comparable case groups using an estimate of the mean sojourn time (mean preclinical duration)
Number of subjects: 0
Study 12486753 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for defining comparable case groups
Number of subjects: 0
Study 10857963 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms (CES-D > or =22)
Number of subjects: 183
Study 10857963 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms
Number of subjects: 183
Study 10857963 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 183
Study 9104712 — intervention group
Group type: COMPARATOR
Intervention: Inlay with Panavia Ex resin (isthmus width of one third the intercuspal distance)
Number of subjects: 50
Study 9104712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay with Panavia Ex resin (isthmus width equal to that in group 1)
Number of subjects: 50
Study 9104712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay with Panavia Ex resin (isthmus width of half the intercuspal distance)
Number of subjects: 50
Study 9104712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay with Panavia Ex resin (isthmus width equal to group 3 with lingual and proximal preparation)
Number of subjects: 50
Study 9104712 — intervention group
Group type: COMPARATOR
Intervention: Onlay cemented with zinc phosphate cement (positive control)
Number of subjects: 50
Study 8064017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegratol (carbamazepine)
Number of subjects: 1
Study 8064017 — intervention group
Group type: COMPARATOR
Intervention: Control periods (before and after drug administration)
Number of subjects: 1
Study 3055922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg nightly (Stratum 1)
Number of subjects: 334
Study 3055922 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily (Stratum 1)
Number of subjects: 334
Study 3055922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg nightly (Stratum 2)
Number of subjects: 334
Study 3055922 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily (Stratum 2)
Number of subjects: 334
Study 3055922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (both strata)
Number of subjects: 334
Study 3055922 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (both strata)
Number of subjects: 334
Study 3055922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 334
Study 31770446 — intervention group
Group type: COMPARATOR
Intervention: Periarticular injection (PAI) with extended-release bupivacaine 266 mg and 20 mL of 0.5% bupivacaine hydrochloride
Number of subjects: 70
Study 31770446 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with extended-release bupivacaine 266 mg
Number of subjects: 70
Study 31770446 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70
Study 31770446 — intervention group
Group type: COMPARATOR
Intervention: PAI group
Number of subjects: 70
Study 31770446 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB group
Number of subjects: 70
Study 31719005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (5 g intravenous before anesthesia induction and 5 g in cardioplegic solution)
Number of subjects: 50
Study 31719005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C
Number of subjects: 50
Study 31719005 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo - normal saline)
Number of subjects: 50
Study 28749549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (2 biweekly infusions of 1g each)
Number of subjects: 24
Study 28749549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28749549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 24
Study 25008903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap1 booster
Number of subjects: 34
Study 25008903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap5 booster
Number of subjects: 34
Study 22416896 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) incorporated into a structured education programme
Number of subjects: 0
Study 22416896 — intervention group
Group type: COMPARATOR
Intervention: Urine glucose monitoring incorporated into a structured education programme
Number of subjects: 0
Study 22416896 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0
Study 22416896 — intervention group
Group type: COMPARATOR
Intervention: Urine glucose monitoring
Number of subjects: 0
Study 20609381 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific group (3 additional sessions of serial targeting practice)
Number of subjects: 18
Study 20609381 — intervention group
Group type: COMPARATOR
Intervention: General arm use group (3 training sessions of increased but non-task specific use of the hemiparetic arm)
Number of subjects: 18
Study 18051001 — intervention group
Group type: EXPERIMENTAL
Intervention: PREMA (PM)
Number of subjects: 36
Study 18051001 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalustre (OP)
Number of subjects: 36
Study 18051001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products (PREMA and Opalustre)
Number of subjects: 36
Study 16040019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell based dressing with living allogenic keratinocytes
Number of subjects: 40
Study 16040019 — intervention group
Group type: COMPARATOR
Intervention: Microcarriers kept in culture medium overnight (Control)
Number of subjects: 40
Study 11911626 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cannulation of the ascending aorta
Number of subjects: 0
Study 11911626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulation of the distal aortic arch
Number of subjects: 0
Study 11911626 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusionist interventions
Number of subjects: 0
Study 11820954 — intervention group
Group type: EXPERIMENTAL
Intervention: 2HRZS/4HR plus vaccine of Mycobacterium vaccae
Number of subjects: 70
Study 11820954 — intervention group
Group type: COMPARATOR
Intervention: 2HRZS/4HR
Number of subjects: 70
Study 11820954 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-6 sensitive antituberculous drugs and vaccine of Mycobacterium vaccae
Number of subjects: 70
Study 7852453 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (dressings and variable ambient temperature for comfort)
Number of subjects: 20
Study 7852453 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (without dressings and variable ambient temperature for comfort)
Number of subjects: 20
Study 7852453 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (without dressings and ambient temperature of 25 degrees C, electromagnetic heaters for comfort)
Number of subjects: 20
Study 7852453 — intervention group
Group type: COMPARATOR
Intervention: Group IV (healthy volunteers)
Number of subjects: 20
Study 2682215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR4 (50/200)
Number of subjects: 20
Study 1249190 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fasting
Number of subjects: 0
Study 1249190 — intervention group
Group type: EXPERIMENTAL
Intervention: No carbohydrate hypocaloric diet (800 kcal)
Number of subjects: 0
Study 1249190 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diets with at least 50 g of carbohydrate
Number of subjects: 0
Study 31258526 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose mesenchymal stem cells (darvadstrocel, formerly Cx601)
Number of subjects: 0
Study 31258526 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro complement-dependent cytotoxicity (CDC) studies
Number of subjects: 0
Study 31258526 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose mesenchymal stem cells (ASC)
Number of subjects: 0
Study 31258526 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion of CD46
Number of subjects: 0
Study 28638273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam infusion (0.3 mg/kg bolus followed by 65 µg/kg/h infusion)
Number of subjects: 60
Study 28638273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.3 mg/kg bolus followed by 180 µg/kg/h infusion)
Number of subjects: 60
Study 28638273 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, equal to ketamine infusion)
Number of subjects: 60
Study 26042362 — intervention group
Group type: EXPERIMENTAL
Intervention: CYT003 (0.3 mg)
Number of subjects: 365
Study 26042362 — intervention group
Group type: EXPERIMENTAL
Intervention: CYT003 (1 mg)
Number of subjects: 365
Study 26042362 — intervention group
Group type: EXPERIMENTAL
Intervention: CYT003 (2 mg)
Number of subjects: 365
Study 26042362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 23466396 — intervention group
Group type: COMPARATOR
Intervention: Normal Protein (NP; 14% of energy from protein)
Number of subjects: 25
Study 23466396 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-High Protein (MHP; 25% of energy from protein)
Number of subjects: 25
Study 23466396 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP; 50% of energy from protein)
Number of subjects: 25
Study 21257196 — intervention group
Group type: EXPERIMENTAL
Intervention: RO-14 (1750-19950 IU of anti-FXa activity)
Number of subjects: 12
Study 19589406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin seal
Number of subjects: 300
Study 19589406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachosil
Number of subjects: 300
Study 16500175 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week neuromuscular training program
Number of subjects: 36